A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV. - Steinbild, S.; Mros, K.; Frost, A.; Morant, R.; Gillessen, S.; Dittrich, C.; Strumberg, D.; Hochhaus, A.; Hanauske, A.-R.; Edler, L.; Burkholder, I.; Scheulen, M.; et al. (British Journal of Cancer, 2007)